newsfilter
← Latest News
Business Wire·

Elan Advises Shareholders to Withdraw Any Acceptances of the Royalty Pharma Offer and Not to Tender Any Further Acceptances into This Lapsed Offer*

DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan or the Company) today advises Elan Shareholders to withdraw any acceptances of Royalty Pharma’s Offer without delay and not to tender any further acceptances. Following the outcome of the Elan EGM yesterday morning, and in accordance with the terms of the Royalty Pharma Offer, the Royalty Pharma Offer has now lapsed*.